Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
From Our Editors · Podcast
Learn what's fueling San Diego's biotech investment and partnership opportunities
Sponsored · Whitepaper
Leveraging technology & expertise to ensure a continual journey from trials to treatments
PRA Health Sciences
